Cizzle Biotechnology Holdings plc (LSE:CIZ) has agreed a £500,000 subscription at 0.8 pence a share with existing shareholder Frazer Lang, in two tranches, and the conversion of £250,000 of his loan notes into shares. The money is to fund early adoption of its CIZ1B lung cancer blood test in the US.

What was announced

On Monday 26 October 2026, Cizzle Biotechnology Holdings plc (LSE:CIZ) (CIZ), whose shares trade on the Main Market of the London Stock Exchange, announced a direct subscription to raise £500,000 before expenses. The release was headlined "£500,000 Subscription, conversion of loan notes". The sole subscriber is Frazer Lang, whom the company describes as a long-standing investor and existing shareholder. No director is named as taking part.

The subscription covers 62,500,000 new ordinary shares at 0.8 pence each and is split in two. Tranche 1 raises £300,000 through 37,500,000 shares, with admission expected on or around 30 October 2026. Tranche 2 raises £200,000 through 25,000,000 shares, with admission expected on or around 6 January 2027. The subscription is not underwritten. Tranche 2 depends on there being no material adverse change, compliance with undertakings, continued listing and trading on the Main Market, and no insolvency event. The announcement does not state a discount or premium to the market price.

Warrants and loan note conversion

Each subscription share comes with a warrant, giving 62,500,000 new warrants exercisable at 1.2 pence until 1 October 2031. Of these, 25,000,000 depend on Tranche 2 admission. The investor's 22,500,000 existing warrants are also being repriced to 1.2 pence: 12,500,000 from 2 pence and 10,000,000 from 2.5 pence. All their expiry dates move to 1 October 2031.

Separately, £250,000 of convertible loan notes issued to Mr Lang under a facility announced on 2 April 2026 will be converted at 1.4 pence per share. The notes were drawn between May and July 2026. The conversion creates 17,857,143 new shares, due to be issued on or around 30 October. After conversion, the investor will hold no loan notes. The announcement does not mention interest on the notes.

In total, 55,357,143 new shares are expected to be admitted on or around 30 October, giving 480,320,345 ordinary shares in issue, each with one vote. The company said the subscription shares will be about 12.37% of the enlarged share capital once all subscription and conversion shares are admitted.

Until Tranche 2 completes, Cizzle has agreed not to take on financial debt or grant security without consent. For 12 months, it must also offer Mr Lang the chance to fund any share issue in full or join on the same terms as others.

The CIZ1B test and use of proceeds

The money will provide working capital to promote adoption of the CIZ1B test in the US and to progress partner agreements in the UK, including with the NHS, and elsewhere. The CIZ1B Biomarker Blood Test for Lung Cancer is a laboratory-developed test. It measures a biomarker linked to early-stage lung cancer from small blood samples.

The test was validated and accredited under CLIA at OmniHealth Diagnostics in June 2026. Licensing partner Cizzle Bio Inc then made it available to licensed providers in the Dallas-Fort Worth and San Antonio areas of Texas, as announced on 22 July 2026. A second lab partner, BioBridge Global, was added in August, and advance royalties were restructured on 15 October. The licences cover North America and the Caribbean.

Executive chairman Allan Syms pointed to the test being "validated in a CLIA accredited laboratory in the USA" and set out plans to invest in early adoption. Mr Lang said the task now is adoption, which needs funding, and that he will keep supporting the US commercial build and UK opportunities.

What to watch next

Key dates are admission on 30 October and Tranche 2 in January 2027. Investors may also watch for US test volumes, royalty income and any NHS agreement. No revenue guidance was given.